Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, Astrazeneca, EMD, Intrommune, Karyopharm, Sinovac, Theratechnologies.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Active, Angelini, Angiotensin, Arvelle, Astrazeneca, Beximco, BMS, BNC, Connectyx, Diamond, Evotec, Famar, Gensight, Golden, Molecular Partners, Neogenomics, Novartis, Novavax, Serum Institute, Sio, Sunshine, Wuxi.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Agenus, Aldeyra, Aligos, Atea, Biogen, Botanix, Calliditas, Codiak, Corvus, Crinetics, Curevac, Dynavax, Eucure, Gilead, Golden, I-Mab, Innocare, Neurorx, Reistone, Surface Ophthalmology.

Biopharmas raising money in public or private financings, including: Bioventus, Cybin, Durect, Equillium, Inivata, Iterum, Kaleido, Revolution, Rhythm, Tyme, Utility, V-Bio, Veracyte.

Quarterly snapshots from biopharma companies with marketed products, including: Acceleron, Alexion.

New hires and promotions in the biopharma industry, including: Catamaran, Codexis, Inozyme, Merck, Microbiotica, Nkmax, Pepgen, Secarna, TCR².

The latest global regulatory news, changes and updates affecting biopharma, including: FDA weighing Xeljanz safety results; EMA initiates OPEN collaboration; NICE evaluating guidance processes; TGA seeking comments; USPTO extends program with Japan’s, Korea’s patent offices; NICE recommends Keytruda in NSCLC; Florida researcher indicted.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adamas, Amgen, Applied, Argenx, Biogen, Janssen, Jeil, Merck, Mirum, Rockwell, Vyne, Zosano.